December 16, 2009 (FinancialWire) — Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, reported that it received notification from the NASDAQ Listings Qualification Department that it has regained compliance with NASDAQ listing rules.

As previously announced on November 17, 2009, Achillion received a written notification from the NASDAQ Listings Qualification Department that the company’s stockholders’ equity, as reported in the company’s Quarterly Report on form 10-Q for the quarter ended September 30, 2009 that it filed with the Securities and Exchange Commission, did not comply with the minimum stockholders’ equity requirement of $10,000,000 for continued listing on The NASDAQ Global Market pursuant to NASDAQ Listing Rule 5450(b) (1) (A).

On December 14, 2009, the company received notification from the NASDAQ Listings Qualification Department that it has regained compliance for continued listing on The NASDAQ Global Market by meeting the requirements of the Market Value Standard.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.